CohBar マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	2.9yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

CohBar CEOがいない、あるいは彼らに関するデータがない。

取締役

名称	ポジション	在職期間	報酬	所有権
Pinchas Cohen	Founder & Member of Scientific Advisory Board	2.9yrs	US$273.45k	6.26% $ 91.0k
Nir Barzilai	Founder & Member of Scientific Advisory Board	2.9yrs	US$273.45k	5.85% $ 85.0k
Craig Jalbert	Director	less than a year	データなし	データなし

2.9yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: CWBRの取締役会は経験豊富ではない ( 2.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

CohBar マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

High number of new and inexperienced directors

CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

High number of new and inexperienced directors

CohBar, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Independent Director recently bought US$96k worth of stock

Recent updates

CohBar, Inc.(OTCPK:CWBR) dropped from S&P TMI Index

CohBar, Inc.(OTCPK:CWBR) dropped from NASDAQ Composite Index

CohBar Expects the Trading in its Common Stock to be Suspended Upon the Opening of Business on November 29, 2023 and Nasdaq to File Form 25-NSE with the SEC to Formally Delist CohBar's Common Stock

Morphogenesis, Inc. cancelled the acquisition of CohBar, Inc. (NasdaqCM:CWBR) in a reverse merger transaction.

New major risk - Share price stability

Morphogenesis, Inc. and Cohbar, Inc. Announce Positive Results from Phase 1B Trial of Ifx-Hu2.0, A Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Morphogenesis, Inc. entered into a definitive agreement to acquire CohBar, Inc. (NasdaqCM:CWBR) for approximately $130 million in a reverse merger transaction.

High number of new and inexperienced directors

CohBar, Inc. to Report Q3, 2022 Results on Nov 08, 2022

CohBar stock gains on 1-for-30 reverse stock split

CohBar, Inc. to Report Q2, 2022 Results on Aug 15, 2022

CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

Here's Why We're Watching CohBar's (NASDAQ:CWBR) Cash Burn Situation

CohBar Announces Extension of Nasdaq Compliance Period

CohBar, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$2.17

High number of new and inexperienced directors

CohBar, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target decreased to US$5.63

Independent Director recently bought US$96k worth of stock

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity

High number of new directors

CohBar, Inc. Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

CohBar, Inc.(NasdaqCM:CWBR) dropped from Russell 3000E Index

CEO & Director Steven Engle has left the company

Price target decreased to US$6.10

CohBar appoints Joseph Sarret as CEO and Director

CohBar, Inc. Announces the Selection of CB5138-3

New 90-day high: US$1.65

CohBar, Inc. Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS

CohBar collaborates with NIAID for CB5064 analogs in COVID-19-related ARDS

New 90-day high: US$1.54

CohBar, Inc. Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome Model

New 90-day high: US$1.21

CohBar EPS in-line

CohBar, Inc. to Report Q3, 2020 Results on Nov 16, 2020

CohBar (CWBR) Investor Presentation - Slideshow

CohBar, Inc. Announces New Preclinical Data Demonstrating That Combination of A Cb5138 Analog with nintedanib

CohBar, Inc. has completed a Composite Units Offering in the amount of $15.006 million.

New 90-day low - US$1.36

CohBar, Inc. to Report Q2, 2020 Results on Aug 13, 2020

New 90-day low - US$1.46

CEO（最高経営責任者

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04